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Emanuel and colleagues’ meta-analysis found that phase I
studies are very safe.1 However, the accompanying editorial
mentioned that phase I studies are a “secret realm” and that
“most studies are conducted outside academic medical centres
at private facilities run by pharmaceutical companies or contract
research organisations.”2
After a major safety problem at a commercial phase I facility
in 2006,3 the UKMedicines and Healthcare products Regulatory
Agency (MHRA) introduced an accreditation scheme to enhance
phase I safety standards in the UK. There are now four publicly
funded phase I accredited clinical research facilities in the UK
that have been open to non-commercial facilities since 2013.
These include one university-hospital partnership (the
Southampton National Institute for Health Research (NIHR)
Wellcome Trust Clinical Research Facility) funded by the
National Institute for Health Research. This provides an
environment for early phase studies within the heart of an acute
NHS hospital along with academic input from local university
investigators. Phase I studies in patient populations and healthy
volunteers are a crucial part of drug development. The UK
Department of Health NIHR experimental medicine
infrastructure has created a setting that delivers industry and
publicly funded phase I trials while allowing recruitment from
the entire UK population.
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